Aims to provide exposure to DNA sequencing technology, gene editing, CRISPR, therapeutics, agricultural biology, and molecular diagnostics. These innovations are increasing precision, restructuring health care, agriculture, pharmaceuticals, and enhancing the quality of life.
- Type: Active Equity
- Typical # of Holdings: 30-50
- Inception: Oct. 2014
- Portfolio Manager: Catherine Wood
This actively managed equity strategy seeks long-term capital growth by investing in the US listed securities, including ADRs, of companies focused on the genomics revolution. Companies within this strategy aim to capture the substantial benefits of new products and services associated with technological and scientific developments in DNA sequencing, gene editing, targeted therapeutics, bioinformatics, and agricultural biology.
|Strategy||ETF||Managed Account||Mutual Fund|
|ARK Genomic Revolution||In Japan|
The content presented does not constitute investment advice, should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. Certain of the statements contained on this website may be statements of future expectations and other forward-looking statements that are based on ARK’s current views and assumptions, and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Please remember that there are inherent risks involved with investing in the markets, and your investments may be worth more or less than your initial investment upon redemption. There is no guarantee that ARK’s objectives will be achieved. Further, there is no assurance that any strategies, methods, sectors, or any investment programs herein were or will prove to be profitable, or that any investment recommendations or decisions we make in the future will be profitable for any investor or client. Professional money management is not suitable for all investors. For full disclosures, please go to our Terms & Conditions page.
Actively managed, high conviction portfolio
Exposure to the intersection of health care and technology
Benchmark agnostic with low overlap to broad market indicies
Research process driven by ARK’s Open Research Ecosystem
Chief Executive Officer
Chief Investment Officer
Chief Executive Officer
Chief Investment Officer
Cathie registered ARK Investment Management LLC (“ARK”) as an investment adviser with the U.S. Securities and Exchange Commission in January 2014. With over 40 years of experience identifying and investing in innovation, Cathie founded ARK to focus solely on disruptive innovation while adding new dimensions to research. Through an open approach that cuts across sectors, market capitalizations, and geographies, Cathie believes that ARK can identify large-scale investment opportunities in the public markets resulting from technological innovations centered around DNA sequencing, robotics, artificial intelligence, energy storage, and blockchain technology. As Chief Investment Officer (“CIO”) and Portfolio Manager, Cathie led the development of ARK’s philosophy and investment approach and has ultimate responsibility for investment decisions.
Prior to ARK, Cathie spent twelve years at AllianceBernstein as CIO of Global Thematic Strategies where she managed over $5 billion. Cathie joined Alliance Capital from Tupelo Capital Management, a hedge fund she co-founded, which in 2000, managed approximately $800 million in global thematic strategies. Prior to her tenure at Tupelo Capital, she worked for 18 years with Jennison Associates LLC as Chief Economist, Equity Research Analyst, Portfolio Manager and Director. She started her career in Los Angeles, California at The Capital Group as an Assistant Economist. Cathie received her Bachelor of Science, summa cum laude, in Finance and Economics from the University of Southern California in 1981.
Cathie has been recognized as an influential fund manager across various outlets. In 2018, editors at Bloomberg acknowledged Cathie by selecting her to its second annual Bloomberg 50 list of people across business, entertainment, finance, politics, technology, and science who have defined global business. Additionally, Fortune named Cathie to its exclusive roundtable of experts in the annual Fortune Investors Guide: The Best Investing Advice for 2019 From Fortune’s Experts. In 2016, Cathie received the “Women in Finance – Outstanding Contribution Award” from Market Media. Cathie also has been a featured speaker at the World Economic Forum (China) in 2016 & 2017, the World Strategic Forum (Miami) in 2017, The Sohn Hearts and Minds Investment Leaders Conference (Australia) in 2018 and 2019, and Singularity University’s Exponential Finance in 2017 and Global Summit in 2019.
In 2018, Cathie launched the Duddy Innovation Institute at her alma mater, Notre Dame Academy in Los Angeles. The institute offers a challenging educational experience for young women eager to stretch their learning beyond the boundaries of traditional acquisition of knowledge, while influencing a new way of thinking and learning throughout campus.
*The Adviser did not pay a fee to be considered for or granted any awards. The Adviser did not pay a fee or was required to be a member of an organization to be invited as a speaker at any of the noted events. For full Award Disclosure please go to our Terms & Conditions page. Past performance is not a guarantee of future results.
Catherine’s favorite innovator
Arcticles from Catherine Wood:See all articles
The coronavirus has thrown the markets for a loop, understandably. Half of the solution is understanding the problem, so we are reassured by the universal and unified policy responses globally.
Director of Research
Director of Research
Brett joined ARK in February 2014 and has worked alongside Cathie for almost 15 years since their time at AllianceBernstein. As Director of Research, Brett guides and manages the proprietary research of ARK’s investment team. The team recognizes that disruptive innovation demands a dynamic and universal approach. By researching across sectors, industries and markets, ARK’s investment team seeks to gain a deeper understanding of the convergence and market potential of disruptive innovations, and thus size investment opportunities more appropriately.
Prior to ARK, Brett served as a Vice President and Senior Analyst on the Research on Strategic Change team at AllianceBernstein. In that role, Brett conducted thematic research, served on the thematic portfolios strategy committee under Cathie Wood’s stewardship, and advised portfolio managers across asset classes. His research topics included Global Energy in the Face of Carbon Dioxide Regulation; Social Media and the Rise of Facebook; the Reformation of the Financial Services Landscape; and the Emergence of Electric Vehicles. He also is the Founder and Principal at iamB Consulting, providing strategy consulting to early stage startups. Prior to 2007, Brett worked in business development in the Radio-Frequency Identification industry after serving as a founding teacher at a charter high school in Los Angeles. Brett earned his Bachelor of Science in Mechanical Engineering at the Massachusetts Institute of Technology (MIT).
Brett’s favorite innovator
Arcticles from Brett Winton:See all articles
Simon joined ARK as an Analyst on the Genomic Revolution strategy in October 2018. His focus is on next generation DNA sequencing, molecular diagnostics, bioinformatics, and synthetic biology.
Prior to ARK, Simon was an engineering intern at Tissue Analytics—a software firm that utilizes computer vision and machine learning to analyze chronic wounds. Previously, Simon was a research intern at South Texas Accelerated Research Therapeutics (START) and Oncopath Laboratory, where he focused on novel anticancer agents and molecular tissue profiling, respectively. Simon graduated from the Johns Hopkins University in 2018 with a Bachelor of Science in Chemical and Biomolecular Engineering and a focus on computational biomedicine.
Simon has appeared on Cheddar TV, Investor’s Business Daily, and TD Ameritrade.
Simon’s favorite innovator
Arcticles from Simon Barnett:See all articles
Alexandra “Ali” joined ARK as an Analyst on the Genomic Revolution strategy in February 2020. She focuses on gene editing, stem cell and novel immunotherapy technologies.
Prior to ARK, Ali conducted clinical cancer research at the Memorial Sloan Kettering Cancer Center and the Montefiore Medical Center; and was a Senior Research Program Manager at IBM Watson Health. Ali incorporated her own consulting firm in 2018. Ali has a Bachelor of Arts from McGill University and a Masters in Epidemiology and Community Health from New York Medical College. She has additional training from the MIT Labs in Human-Computer Interaction for User Experience Design.
Ali has published over 25 articles spanning cancer research, AI and space medicine. She has three filed patents and received the Manager’s Choice Award in 2017 and 2018, and the Rookie of the Year Award in 2017 from IBM Watson Health.
Alexandra’s favorite innovator